Although the antiapoptotic, mitogenic, and anabolic effect of GH is undeniable, however, the exact mechanism by which tumor cells are unprotected remains unknown; thus, the threat of a potential adverse effect from GH, including increased future cancer risk or tumor recurrence, precludes its clinical use in oncological patients. The gene discussed is GH1; the disease is neoplasm.